PACIRA BIOSCIENCES INC (PCRX) Stock Price, Quote, News and Overview
NASDAQ:PCRX - Nasdaq - US6951271005 - Common Stock - Currency: USD
PCRX Quote, Performance and Key Statistics
26.98
+0.58 (+2.2%)
The current stock price of PCRX is 26.98 USD. In the past month the price increased by 7.28%. In the past year, price decreased by -5.57%.
PCRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 55.66 | 725.82B | ||
| JNJ | JOHNSON & JOHNSON | 15.25 | 368.66B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.07 | 320.10B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.07 | 230.97B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.59 | 226.33B | ||
| MRK | MERCK & CO. INC. | 10.05 | 196.54B | ||
| PFE | PFIZER INC | 7.29 | 132.98B | ||
| SNY | SANOFI-ADR | 11.15 | 120.47B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.58B | ||
| GSK | GSK PLC-SPON ADR | 9.19 | 82.77B | ||
| ZTS | ZOETIS INC | 28 | 75.06B | ||
| HLN | HALEON PLC-ADR | 22.31 | 49.21B |
Related stock screener links
About PCRX
Company Profile
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 790 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
Company Info
PACIRA BIOSCIENCES INC
2000 Sierra Point Parkway, Suite 900
Brisbane California CALIFORNIA 07054 US
CEO: David Stack
Employees: 789
Phone: 16502428052
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the stock price of PACIRA BIOSCIENCES INC today?
The current stock price of PCRX is 26.98 USD. The price increased by 2.2% in the last trading session.
What is the ticker symbol for PACIRA BIOSCIENCES INC stock?
The exchange symbol of PACIRA BIOSCIENCES INC is PCRX and it is listed on the Nasdaq exchange.
On which exchange is PCRX stock listed?
PCRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PACIRA BIOSCIENCES INC stock?
13 analysts have analysed PCRX and the average price target is 39.78 USD. This implies a price increase of 47.44% is expected in the next year compared to the current price of 26.98. Check the PACIRA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PACIRA BIOSCIENCES INC worth?
PACIRA BIOSCIENCES INC (PCRX) has a market capitalization of 1.25B USD. This makes PCRX a Small Cap stock.
How many employees does PACIRA BIOSCIENCES INC have?
PACIRA BIOSCIENCES INC (PCRX) currently has 789 employees.
What are the support and resistance levels for PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a support level at 26.64 and a resistance level at 26.99. Check the full technical report for a detailed analysis of PCRX support and resistance levels.
Is PACIRA BIOSCIENCES INC (PCRX) expected to grow?
The Revenue of PACIRA BIOSCIENCES INC (PCRX) is expected to grow by 6.71% in the next year. Check the estimates tab for more information on the PCRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PACIRA BIOSCIENCES INC (PCRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PCRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PCRX, evaluating the profitability, health, valuation and growth aspects
- PACIRA BIOSCIENCES INC (PCRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PACIRA BIOSCIENCES INC (PCRX) Sales and EPS estimates to see what analysts future expectations are.
- PACIRA BIOSCIENCES INC (PCRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PACIRA BIOSCIENCES INC (PCRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PACIRA BIOSCIENCES INC (PCRX) Stock Chart to make your own analysis
- PACIRA BIOSCIENCES INC (PCRX) Latest news and press-releases to stay up to date.
Does PACIRA BIOSCIENCES INC (PCRX) stock pay dividends?
PCRX does not pay a dividend.
When does PACIRA BIOSCIENCES INC (PCRX) report earnings?
PACIRA BIOSCIENCES INC (PCRX) will report earnings on 2025-07-28, after the market close.
What is the Price/Earnings (PE) ratio of PACIRA BIOSCIENCES INC (PCRX)?
The PE ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.4. This is based on the reported non-GAAP earnings per share of 3.21 and the current share price of 26.98 USD. Check the full fundamental report for a full analysis of the valuation metrics for PCRX.
What is the Short Interest ratio of PACIRA BIOSCIENCES INC (PCRX) stock?
The outstanding short interest for PACIRA BIOSCIENCES INC (PCRX) is 12.49% of its float. Check the ownership tab for more information on the PCRX short interest.
PCRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to PCRX. When comparing the yearly performance of all stocks, PCRX turns out to be only a medium performer in the overall market: it outperformed 62.32% of all stocks.
PCRX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PCRX. While PCRX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
PCRX Financial Highlights
Over the last trailing twelve months PCRX reported a non-GAAP Earnings per Share(EPS) of 3.21. The EPS increased by 6.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.97% | ||
| ROE | -11.87% | ||
| Debt/Equity | 0.48 |
PCRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to PCRX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -10.41% and a revenue growth 6.71% for PCRX